Immunomodulatory effect of pentoxifylline during allograft rejection: Involvement of tumor necrosis factor-α and adhesion molecules

Transplantation

Volumn 69, Issue 6, 2000, Pages 1102-1107

  Noel, Christian ^a   Copin, Marie Christine ^a   Hazzan, Marc ^a   Labalette, Myriam ^a   Susen, Sophie ^a   Lelievre, Gaston ^a   Dessaint, Jean Paul ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CADAVER KIDNEY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; KIDNEY GRAFT REJECTION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034719665     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200003270-00014     Document Type: Article

References (54)

1. Bianco JA, Almgren J, Kern DL, et al. Evidence that oral pentoxifylline reverses acute renal dysfunction in bone marrow transplant recipients receiving amphotericin B and cyclosporine. Transplantation 1991; 51: 925.
2. Leimenstoll G, Zabel P, Schroeder P, Schlaak M, Niedermayer W. Suppression of OKT3-induced tumor necrosis factor α formation by pentoxifylline in renal transplant recipients. Transplant Proc 1993; 25: 561.
3. Vincenti FG, Vasconcelos M, Birnbaum JL, et al. Pentoxifylline reduces the first-dose reactions following OKT3. Transplant Proc 1993; 25 (Suppl 1): 57.
4. Alegre ML, Gastaldello K, Abramowicz D, et al. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 1991; 52: 674.
5. Noël C, Hazzan M, Labalette M, et al. Improvement in the outcome of rejection with pentoxifylline in renal transplantation. Transplantation 1998; 65: 385.
6. Tannenbaum CS, Hamilton TA. Lipopolysaccharide-induced gene expression in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP. J Immunol 1989; 142: 1274.
7. Neuner P, Klosner G, Schauer E, et al. Pentoxifylline in vivo down-regulates the release of IL-1β, IL-6, IL-8 and tumor necrosis factor-α by human peripheral blood mononuclear cells. Immunology 1994; 83: 262.
8. Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-α production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230.
9. Han J, Thompson P, Beutler B. Dexamethazone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990; 172: 391.
10. Kiely PD, Gillepsie KM, Oliveira DB, et al. Oxypentifylline inhibits TNFa mRNA transcription and protects against arthritis in mercuric chloride treated Brown Norway rats. Eur J Immunol 1995; 70: 2899.
11. Zabel P, Schonharting MM, Wolter DT, Schade UF. Oxypentifylline in endotoxaemia. Lancet 1989; 2: 1474.
12. Bemelmans MH, Abramowicz D, Gouma DJ, Goldman M, Buurman WA. In vivo T cell activation by anti-CD3 monoclonal antibody induces soluble TNF receptor release in mice: effects of pentoxifylline, methylprednisone, anti-TNF, and anti-IFN-gamma antibodies. J Immunol 1994; 153: 499.
13. Dezube BJ, Fridovich-Keil JL, Bouvard I, Lange RF, Pardee AB. Pentoxifylline and wellbeing in patients with cancer. Lancet 1990; 335: 662.
14. Harada H, Ishizaka A, Yonemaru M, et al. The effect of aminophylline and pentoxifylline on multiple organ damage after Escherichia coli sepsis. Am Rev Respir Dis 1989; 140: 974.
15. Noel P, Nelson S, Bokulic R, et al. Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality. Life Sci 1990; 47: 1023.
16. Aukrust P, Liabakk NB, Muller F, Lien E, Espevik T, Froland SS. Serum levels of tumor necrosis factor-α (TNF α) and soluble TNF receptors in human immunodeficiency virus type 1 infection. Correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994; 169: 420.
17. Fahey JL. Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infection. Clin Diagn Lab Immunol 1998; 5: 597.
18. Lien E, Liabakk NB, Johnsen AC, Nonstad U, Sundan A, Espevik T. Polymorphonuclear granulocytes enhance lipopolysaccharide-induced soluble p75 tumor necrosis factor receptor release from mononuclear cells. Eur J Immunol 1995; 25: 2714.
19. Hohmann HP, Brockhaus M, Baeuerle PA, Remy R, Kolbeck R, van Loon AP. Expression of the types A and B tumor necrosis factor (TNF) receptors is independently regulated, and both receptors mediate activation of the transcription factor NF-κB. TNF α is not needed for induction of a biological effect via TNF receptors. J Biol Chem 1990; 265: 2249.
20. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45: 491.
21. + T cell infiltration. J Immunol 1992; 149: 2954.
22. Mackay F, Loetscher H, Stueber D, Gehr G, Lesslauer W. Tumor necrosis factor α (TNF-α)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med 1993; 177: 1277.
23. Haraldsen G, Kvale D, Lien B, Farstad IN, Bransdtzaeg P. Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cells. J Immunol 1996; 156: 2558.
24. Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187: 584.
25. Gearing AJ, Newman JW. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506.
26. Staak K, Prösch S, Stein J, et al. Pentoxifylline promotes replication of human cytomegalovirus in vivo and in vitro. Blood 1997; 89: 3182.
27. + T cells. Clin Exp Immunol 1994; 95: 465.
28. Liebmann PM, Reibnegger G, Lehofer M, et al. Circadian rhythm of the soluble p75 tumor necrosis factor (sTNF-R75) receptor in humans: a possible explanation for the circadian kinetics of TNF-α effects. Int Immunol 1998; 10: 1393.
29. Aziz N, Nishanian P, Mitsuyasu R, Detels R, Fahey JL. Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol 1999; 6: 89.
30. Copin MC, Noël C, Hazzan M, et al. Diagnostic and predictive value of an immunohistochemical profile in asymptomatic acute rejection of renal allografts. Transplant Immunol 1995; 3: 229.
31. Bemelmans MH, van Tits LJ, Buurman WA. Tumor necrosis factor: function, release and clearance. Crit Rev Immunol 1996; 16: 1.
32. Rogy MA, Coyle SM, Oldenburg HS et al. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg 1994; 178: 132.
33. van Deuren M, Frieling JT, van der Ven-Jongekrijg J et al. Plasma patterns of tumor necrosis factor-α (TNF) and TNF-soluble receptors during acute meningococcal infections and the effect of plasma exchange. Clin Infect Dis 1998; 26: 918.
34. van der Poll T, Jansen J, van Leenen D, et al. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 1993; 168: 955.
35. Boehme M, Waldherr WR, Kist A et al. Kinetics of soluble TNF-receptors and soluble adhesion molecules ICAM-1, E-selectin and VCAM-1 under systemic rhTNFα therapy. Eur J Clin Invest 1996; 26: 404.
36. Lang T, Krams SM, Villanueva JC, Cox K, So S, Martinez OM. Differential patterns of circulating intercellular adhesion molecule-1 (cICAM-1) and vascular cell adhesion molecule-1 (cV-CAM-1) during liver allograft rejection. Transplantation 1995; 27: 584.
37. Alcalde G, Merino J, Sans S, et al. Circulating during adhesion molecules kidney allograft rejection. Transplantation 1995; 59: 1695.
38. Fuggle SV, Koo DDH. Cell adhesion molecules in clinical renal transplantation: overview. Transplantation 1998; 65: 763.
39. Hill PA, Main IW, Atkins R. ICAM-1 and VCAM-1 in human renal allograft rejection. Kidney Int 1995; 47: 1383.
40. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL-1 and interferon-γ: tissue distribution, biochemistry, and function of natural adherence molecule (ICAM-1). J Immunol 1986; 137: 245.
41. Imagawa DK, Larsen CP, Morris PJ. The role of tumor necrosis factor in allograft rejection. Transplantation 1991; 51: 57.
42. Hauser IA, Riess R, Hausknecht B, Thuringer H, Sterzel RB. Expression of cell adhesion molecules in primary renal disease and renal allograft rejection. Nephrol Dial Transplant 1997; 12: 1122.
43. Pober JS, Slowik MR, De Luca LG, Ritchie AJ. Elevated cyclic AMP inhibits endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1. J Immunol 1993; 150: 5114.
44. Bishop GA, Hall BM. Expression and lymphocyte adhesion molecules in the human kidney. Kidney Int 1989; 36: 1078.
45. Mampaso F, Sanchez-Madrid F, Marcen R, et al. Expression of adhesion molecules in allograft renal dysfunction: a distinct diagnostic pattern in rejection and cyclosporine nephrotoxicity. Transplantation 1993; 56: 687.
46. Alpers CE, Hudkins KL, Davis CL, et al. Expression of vascular cell adhesion molecule-1 in kidney allograft rejection. Kidney Int 1993; 44: 805.
47. Ates E, Sharma P, Erkasap S, et al. Cyclosporine nephrotoxicity in the ischemic kidney and the protective effect of pentoxyfylline: a study in the rat. Transplantation 1996; 62: 864.
48. Carrier M, Pelletier GB, White M, Bois D, Pelletier LC. Effect of pentoxifylline on renal toxicity of cyclosporine: results of a clinical trial after heart transplantation. J Heart Lung Transplant 1996; 15: 1179.
49. Khabar KS, Dzimiri M, Parhar RS, et al. Pentoxifylline (PTX) selectively potentiates cyclosporine (CsA)-mediated suppression of cell-mediated lymphototoxicity: median-effect analysis for the drug dose reductions in PTX and CsA combination treatment. Transplantation 1996; 61: 838.
50. Briggs WA, Eustace J, Mathew S, et al. Pentoxifylline potentiates in vitro lymphocyte suppression by glucocorticoids and immunosuppressive drugs. J Clin Pharmacol 1998; 38: 561.
51. Richard M, Hoskin DW. Inhibition of anti-CD3 antibody-induced mouse T cell activation by pentoxifylline in combination with rapamycin or A77 1726 (leflunomide). Int J Immunopharmacol 1998; 20: 241
52. Neuner P, Klosner G, Pourmojib M, Knobler R, Schwarz T. Pentoxifylline in vitro and in vivo down-regulates the expression of the intercellular adhesion molecule-1 in monocytes. Immunology 1997; 90: 435.
53. Gonzalez-Amaro R, Portales-Perez D, Baranda L, et al. Pentoxifylline inhibits adhesion an activation of human T lymphocytes. J Immunol 1998; 161: 65.
54. + T lymphocyte compartment. Transplantation 1997; 63: 693.